| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TFPI2 |
| Uniprot No | P48307 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-213aa |
| 氨基酸序列 | DAAQEPTG NNAEICLLPL DYGPCRALLL RYYYDRYTQS CRQFLYGGCE GNANNFYTWE ACDDACWRIE KVPKVCRLQV SVDDQCEGST EKYFFNLSSM TCEKFFSGGC HRNRIENRFP DEATCMGFCA PKKIPSFCYS PKDEGLCSAN VTRYYFNPRY RTCDAFTYTG CGGNDNNFVS REDCKRACAK ALK |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TFPI2重组蛋白的3篇文献概览：
1. **《Recombinant TFPI2 inhibits hepatocellular carcinoma growth by inducing apoptosis and suppressing angiogenesis》**
- **作者**：Zhang Y, 等
- **摘要**：该研究通过体外和体内实验，发现重组TFPI2蛋白能够诱导肝癌细胞凋亡，并抑制肿瘤血管生成，显著减缓肿瘤生长，提示其潜在的抗肿瘤治疗价值。
2. **《Recombinant human TFPI2 inhibits invasion and metastasis of pancreatic cancer via downregulation of MMP-2 and MMP-9》**
- **作者**：Smith JL, 等
- **摘要**：研究显示，重组人TFPI2通过降低基质金属蛋白酶MMP-2和MMP-9的表达，有效抑制胰腺癌细胞的侵袭和转移能力，为靶向治疗提供了实验依据。
3. **《Expression and purification of functional recombinant TFPI2 in Escherichia coli for biomedical applications》**
- **作者**：Lee H, 等
- **摘要**：该文献优化了在大肠杆菌中高效表达重组TFPI2的工艺，并验证了纯化后蛋白的生物活性，为大规模生产及后续临床应用奠定了基础。
4. **《TFPI2 suppresses Wnt/β-catenin signaling to inhibit colorectal cancer progression》**
- **作者**：Wang X, 等
- **摘要**：研究发现，重组TFPI2通过阻断Wnt/β-catenin信号通路，抑制结直肠癌细胞的增殖和转移，揭示了其在调控关键致癌通路中的作用机制。
(注：以上文献为模拟示例，实际引用请核对真实数据库。)
Tissue Factor Pathway Inhibitor 2 (TFPI2) is a serine protease inhibitor belonging to the Kunitz-type family, primarily known for its role in regulating coagulation and extracellular matrix (ECM) remodeling. It contains three Kunitz-type domains, with the first two domains inhibiting activated factor X (FXa) and tissue factor (TF)/factor VIIa (FVIIa) complexes, while the third domain interacts with proteases involved in ECM degradation, such as plasmin and matrix metalloproteinases (MMPs). Unlike TFPI1. TFPI2 is secreted into the extracellular space and exhibits broader protease specificity.
TFPI2 is expressed in various tissues, including the placenta, liver, and vascular endothelium. It plays dual roles in homeostasis: modulating blood coagulation by suppressing the TF-dependent pathway and maintaining ECM integrity by balancing protease activity. Dysregulation of TFPI2 is linked to pathological conditions. Reduced TFPI2 expression, often due to promoter hypermethylation, is observed in cancers (e.g., pancreatic, gastric, and colorectal), correlating with tumor invasion, metastasis, and poor prognosis. Conversely, elevated TFPI2 levels are associated with cardiovascular diseases, including atherosclerosis and thrombosis, where it may exert protective or pathogenic effects depending on context.
Recombinant TFPI2 (rTFPI2) is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its therapeutic potential. Preclinical research highlights its anti-tumor effects via inhibition of angiogenesis and metastasis, as well as antithrombotic properties. However, challenges remain in optimizing its stability, delivery, and tissue-specific targeting. Current investigations focus on rTFPI2 as a biomarker for early cancer detection and a novel therapeutic agent for coagulation disorders and fibrotic diseases. Its multifaceted roles make TFPI2 a compelling subject for translational research bridging hematology, oncology, and vascular biology.
×
